[ad_1]  Ce médicament fait l’objet d’une surveillance supplémentaire qui permettra d’identifier rapidement les nouvelles informations relatives à la sécurité LONDRES, 3 décembre 2025 /PRNewswire/ — Accord Healthcare a annoncé aujourd’hui le lancement d’Osvyrti (denosumab), un […]

[ad_1] ∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ — Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to […]

[ad_1] LONDON, Oct. 20, 2025 /PRNewswire/ — Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances […]

[ad_1] Hetronifly ist der weltweit erste monoklonale Anti-PD-1-Antikörper (mAb), der für die Erstlinienbehandlung von ES-SCLC (in Kombination mit Carboplatin und Etoposid) zugelassen ist. Hetronifly ist der einzige in Europa zugelassene Anti-PD-1-mAb zur Behandlung von ES-SCLC […]

[ad_1] Hetronifly is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC (in combination with carboplatin and etoposide). Hetronifly is the only anti-PD-1 mAb approved in Europe for the treatment of […]